

Robustly Assess Your Drug's **Cognitive Safety Profile**



Cognitive functions are a vital part of our everyday daily life, and greatly impact our ability to complete work and social activities. Understanding the effect of new pharmaceutical compounds in relation to activities that may introduce risk if cognition is reduced, such as driving or operating machinery, is an important part of drug development.

The Signant SmartSignals® Cognitive Drug Research® system (CDR SYSTEM®) is a state-of-the-art web-based solution offering a validated battery of cognitive tests to assess treatment efficacy and safety. While it can be used in any phase of drug development, its attention battery can be used in early phase trials to evaluate safety and tolerability. The attention battery is part of Signant Health's comprehensive computerized cognitive test solution; measures of memory and executive function are also available.

The CDR System® has been recognized for over 35 years as a leading solution for cognitive testing, and is associated with unrivalled accuracy, sensitivity, simplicity, and interpretability. Our web-based solution follows significant research into evolving industry needs, and investment into the next generation of the most widely validated battery in clinical trials.



Accuracy & sensitivity

Precisely assess aspects of cognition using tasks relevant to everyday life



Interpretability

Interpret changes in cognition with reference to extensive normative distributions



Simple, fast administration

An easy to use web-based solution that can be administered by non-specialists within non-specialist centers

Validated measures and inferences you can trust

Developed by Signant Health and widely accepted internationally, our cognitive tests have been extensively validated and proven to be a precise method of detecting subtle mental changes regardless of the disease, drug development phase, or participant population size or type.

Why choose the CDR System® for early-phase cognitive safety studies?

SIGNANT SMARTSIGNALS®
CDR SYSTEM

- 1 Accurately assess core aspects of attention
- 2 Unrivalled sensitivity
- 3 Enhance interpretation with the largest and most comprehensive normative database in the industry
- 4 Easy-to-use, compliant, web-based platform
- 5 Tests already validated for use in 50+ languages
- 6 Leverage our expert team and scientific support for best practice implementation and data interpretation
- 7 Trusted worldwide for 35+ years
- 8 Developed and delivered by cognition experts

Precise assessment of attention

Understand early-phase signals to drive cognitive safety assessment, tolerability, and dose selection decisions. The Cognitive Drug Research® system attention battery is validated by 35+ years of scientific studies, and comprises three core cognitive tests measuring **power of attention**, **continuity of attention**, and **cognitive reaction time**.



Simple reaction time

Measures alertness and the ability to focus concentration



Digit vigilance

Measures sustained and intensive attention



Choice reaction time


Measures alertness, the ability to focus concentration, and information processing

Our solutions are better together

Use the CDR System® alongside other Signant SmartSignals solutions



eCOA



Electronic Clinician Ratings



Rater Training & Qualification

Explore the Full Suite

WHO IS SIGNANT HEALTH?

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.

